» Articles » PMID: 20658749

Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy

Abstract

Background: The effect of interruption of antiretroviral therapy (ART) on lipoprotein particle subclasses has not been studied. We examined short-term changes in lipids and lipoprotein particles among 332 HIV-infected individuals randomized to interrupt or continue ART in the "Strategies for Management of Antiretroviral Therapy" trial.

Methods: Lipids and lipoprotein particles measured by nuclear magnetic resonance spectroscopy were compared between randomized groups at month 1; associations with inflammatory and coagulation markers (high sensitivity C-reactive protein; interleukin 6; amyloid A; amyloid P; D-dimer; prothrombin fragment 1 + 2) were assessed.

Results: Compared with continuation of ART, treatment interruption resulted in substantial declines in total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride, at month 1 but had little net effect on total/HDL cholesterol ratio [baseline-adjusted mean difference [95% confidence interval (CI)] interruption versus continuation arms: -0.10 (-0.59 to 0.38); P = 0.67]. ART interruption resulted in declines in total, large, and medium very low density lipoprotein (VLDL) particle concentrations (VLDL-p) and total and medium HDL-p. However, there was no change in small HDL-p [baseline-adjusted percentage difference between arms: -4.6% (-13.1%, +5.1% ); P = 0.35], small LDL-p [-5.0% (-16.9%, +8.6%); P = 0.45], or other LDL-p subclasses. Changes in lipid parameters on ART interruption did not differ according to baseline ART class (protease inhibitor versus non-nucleoside reverse transcriptase inhibitor) but were negatively associated both with changes in HIV viral load and with changes in inflammatory and coagulation markers, particularly D-dimer.

Conclusions: These results suggest that ART interruption does not favorably influence overall lipid profile: there was little net effect on total/HDL cholesterol ratio, and no change in small LDL-p or small HDL-p, the lipoprotein particle subclasses most consistently linked to coronary risk. Short-term declines in lipid parameters after ART interruption were not associated with class of ART and may be linked to increases in viral replication, inflammation and coagulation.

Citing Articles

Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection.

Kirichenko T, Myasoedova V, Shimonova T, Melnichenko A, Sviridov D, Sobenin I Biosci Rep. 2018; 38(4).

PMID: 29961673 PMC: 6050190. DOI: 10.1042/BSR20180597.


Acute coronary syndromes in patients with HIV.

Seecheran V, Giddings S, Seecheran N Coron Artery Dis. 2016; 28(2):166-172.

PMID: 27845996 PMC: 5287427. DOI: 10.1097/MCA.0000000000000450.


Lipid Abnormalities and Inflammation in HIV Inflection.

Funderburg N, Mehta N Curr HIV/AIDS Rep. 2016; 13(4):218-25.

PMID: 27245605 PMC: 4977198. DOI: 10.1007/s11904-016-0321-0.


Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Khoury P, Ghislain M, Villard E, Le Goff W, Lascoux-Combe C, Yeni P J Lipid Res. 2015; 56(3):692-702.

PMID: 25573889 PMC: 4340316. DOI: 10.1194/jlr.M054510.


The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.

Rose H, Low H, Dewar E, Bukrinsky M, Hoy J, Dart A Atherosclerosis. 2013; 229(1):206-11.

PMID: 23642913 PMC: 3691344. DOI: 10.1016/j.atherosclerosis.2013.04.010.


References
1.
Fontas E, van Leth F, Sabin C, Friis-Moller N, Rickenbach M, dArminio Monforte A . Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis. 2004; 189(6):1056-74. DOI: 10.1086/381783. View

2.
de Larranaga G, Petroni A, Deluchi G, Alonso B, Benetucci J . Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis. 2003; 14(1):15-8. DOI: 10.1097/00001721-200301000-00004. View

3.
Squires K, Lazzarin A, Gatell J, Powderly W, Pokrovskiy V, Delfraissy J . Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004; 36(5):1011-9. DOI: 10.1097/00126334-200408150-00003. View

4.
Rosenson R, Otvos J, Freedman D . Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002; 90(2):89-94. DOI: 10.1016/s0002-9149(02)02427-x. View

5.
Beheshti I, Wessels L, Eckfeldt J . EDTA-plasma vs serum differences in cholesterol, high-density-lipoprotein cholesterol, and triglyceride as measured by several methods. Clin Chem. 1994; 40(11 Pt 1):2088-92. View